FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Front Vet Sci / Response to Intravenous Allogeneic Equine Cord Blood-Derived...
Frontiers in veterinary science2016; 3; 56; doi: 10.3389/fvets.2016.00056

Response to Intravenous Allogeneic Equine Cord Blood-Derived Mesenchymal Stromal Cells Administered from Chilled or Frozen State in Serum and Protein-Free Media.

Abstract: Equine mesenchymal stromal cells (MSC) are commonly transported, chilled or frozen, to veterinary clinics. These MSC must remain viable and minimally affected by culture, transport, or injection processes. The safety of two carrier solutions developed for optimal viability and excipient use were evaluated in ponies, with and without allogeneic cord blood-derived (CB) MSC. We hypothesized that neither the carrier solutions nor CB-MSC would elicit measurable changes in clinical, hematological, or biochemical parameters. In nine ponies (study 1), a bolus of HypoThermosol(®) FRS (HTS-FRS), CryoStor(®) CS10 (CS10), or saline was injected IV (n = 3/treatment). Study 2, following a 1-week washout period, 5 × 10(7) pooled allogeneic CB-MSCs were administered IV in HTS-FRS following 24 h simulated chilled transport. Study 3, following another 1-week washout period 5 × 10(7) pooled allogeneic CB-MSCs were administered IV in CS10 immediately after thawing. Nine ponies received CB-MSCs in study 2 and 3, and three ponies received the cell carrier media without cells. CB-MSCs were pooled in equal numbers from five unrelated donors. In all studies, ponies were monitored with physical examination, and blood collection for 7 days following injection. CD4 and CD8 lymphocyte populations were also evaluated in each blood sample. In all three studies, physical exam, complete blood cell count, serum biochemistry, and coagulation panel did not deviate from established normal ranges. Proportions of CD4(+) and CD8(+) lymphocytes increased at 168 h postinjection in CB-MSC treatment groups regardless of the carrier solution. Decreases in CD4(+/)CD8(+) double positive populations were observed at 24 and 72 h in CB-MSC-treated animals. There was no difference in viability between CB-MSCs suspended in HTS-FRS and CS10. HTS-FRS and CS10 used for low volume excipient injection of MSC suspensions were not associated with short-term adverse reactions. HTS-FRS and CS10 both adequately maintain CB-MSC viability following hypothermic or frozen simulated transport, respectively. CB-MSCs do not elicit clinical abnormalities, but allogeneic stimulation of CD4(+) and CD8(+) lymphocyte populations may occur. Future studies should include in vitro or in vivo evaluation of cell-mediated or adaptive immunity to autologous, identical allogeneic, or MSC originating from additional unrelated individuals in order to better characterize this response.
Get Full Text
Publication Date: 2016-07-22 PubMed ID: 27500136PubMed Central: PMC4956649DOI: 10.3389/fvets.2016.00056Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper examines the effects of two carrier solutions on equine mesenchymal stromal cells (MSC), which are frequently transported to veterinary clinics in chilled or frozen states. The study tests the safety and efficacy of preserving MSC’s viability during this process and concludes that the two solutions, in conjunction with cord blood-derived (CB) MSC, bring no noticeable alterations in clinical, hematological or biochemical factors in ponies.

Methods

  • The research involved two studies, each with nine ponies as subjects. In the first study, each pony was injected with one of three solutions: HypoThermosol(®) FRS (HTS-FRS), CryoStor(®) CS10 (CS10), or saline, which served as control.
  • In the second study, after a one-week gap, an allogenic CB-MSC was given to the ponies intravenously along with HTS-FRS after a 24-hour simulated chilled transport.
  • A third study involved injecting another pool of allogenic CB-MSC in ponies, with CS10 as the carrier immediately after thawing, following another one-week washout period.
  • The CB-MSCs used were pooled equally from five unrelated donors. The ponies’ physical conditions were monitored, and blood samples were collected for a week post-injection. The lymphocyte populations in the blood samples were also studied.

Results

  • The observations from all three studies showed that the ponies’ physical, blood cell count, serum biochemistry, and coagulation panel measurements did not stray from the normal range after receiving the carrier solutions or the CB-MSC.
  • Alterations in lymphocyte populations, specifically CD4(+) and CD8(+), were noticed 168 hours after the ponies were injected with the CB-MSC treatment, regardless of the carrier solution used.
  • The study also found decreases in the population of double positive CD4(+)CD8(+) lymphocytes 24 and 72 hours after CB-MSC treatment.
  • There were no observable differences in viability between CB-MSCs carried by HTS-FRS and those carried by CS10.

Conclusions and Future Directions

  • The study concluded that neither HTS-FRS nor CS10 resulted in short-term adverse reactions when used for the low-volume injection of MSC suspensions.
  • Both carrier solutions were able to preserve the viability of CB-MSCs following hypothermic or frozen simulated transport.
  • However, CB-MSCs may stimulate allogeneic responses in CD4(+) and CD8(+) lymphocyte populations.
  • In anticipation of future research, the study suggests examining cell-mediated or adaptive immunity to autologous, identical allogeneic, or MSC originating from additional unrelated individuals to better understand the observed responses.

Cite This Article

APA
Williams LB, Co C, Koenig JB, Tse C, Lindsay E, Koch TG. (2016). Response to Intravenous Allogeneic Equine Cord Blood-Derived Mesenchymal Stromal Cells Administered from Chilled or Frozen State in Serum and Protein-Free Media. Front Vet Sci, 3, 56. https://doi.org/10.3389/fvets.2016.00056

Publication

Frontiers in veterinary science
ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 3
Pages: 56
PII: 56

Researcher Affiliations

Williams, Lynn B
  • Department of Biomedical Sciences, University of Guelph , Guelph, ON , Canada.
Co, Carmon
  • Department of Biomedical Sciences, University of Guelph , Guelph, ON , Canada.
Koenig, Judith B
  • Department of Clinical Studies, Ontario Veterinary College, University of Guelph , Guelph, ON , Canada.
Tse, Crystal
  • Department of Biomedical Sciences, University of Guelph , Guelph, ON , Canada.
Lindsay, Emily
  • Department of Biomedical Sciences, University of Guelph , Guelph, ON , Canada.
Koch, Thomas G
  • Department of Biomedical Sciences, University of Guelph , Guelph, ON , Canada.

References

This article includes 43 references
  1. Fortier LA, Nixon AJ, Williams J, Cable CS. Isolation and chondrocytic differentiation of equine bone marrow-derived mesenchymal stem cells.. Am J Vet Res 1998 Sep;59(9):1182-7.
    pubmed: 9736400
  2. Bourzac C, Smith LC, Vincent P, Beauchamp G, Lavoie JP, Laverty S. Isolation of equine bone marrow-derived mesenchymal stem cells: a comparison between three protocols.. Equine Vet J 2010 Sep;42(6):519-27.
    doi: 10.1111/j.2042-3306.2010.00098.xpubmed: 20716192google scholar: lookup
  3. Toupadakis CA, Wong A, Genetos DC, Cheung WK, Borjesson DL, Ferraro GL, Galuppo LD, Leach JK, Owens SD, Yellowley CE. Comparison of the osteogenic potential of equine mesenchymal stem cells from bone marrow, adipose tissue, umbilical cord blood, and umbilical cord tissue.. Am J Vet Res 2010 Oct;71(10):1237-45.
    doi: 10.2460/ajvr.71.10.1237pubmed: 20919913google scholar: lookup
  4. Vidal MA, Kilroy GE, Lopez MJ, Johnson JR, Moore RM, Gimble JM. Characterization of equine adipose tissue-derived stromal cells: adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stromal cells.. Vet Surg 2007 Oct;36(7):613-22.
    doi: 10.1111/j.1532-950X.2007.00313.xpubmed: 17894587google scholar: lookup
  5. Koch TG, Heerkens T, Thomsen PD, Betts DH. Isolation of mesenchymal stem cells from equine umbilical cord blood.. BMC Biotechnol 2007 May 30;7:26.
    doi: 10.1186/1472-6750-7-26pmc: PMC1904213pubmed: 17537254google scholar: lookup
  6. Koch TG, Thomsen PD, Betts DH. Improved isolation protocol for equine cord blood-derived mesenchymal stromal cells.. Cytotherapy 2009;11(4):443-7.
    doi: 10.1080/14653240902887259pubmed: 19513899google scholar: lookup
  7. Hoynowski SM, Fry MM, Gardner BM, Leming MT, Tucker JR, Black L, Sand T, Mitchell KE. Characterization and differentiation of equine umbilical cord-derived matrix cells.. Biochem Biophys Res Commun 2007 Oct 19;362(2):347-53.
    doi: 10.1016/j.bbrc.2007.07.182pubmed: 17719011google scholar: lookup
  8. Williams LB, Tessier L, Koenig JB, Koch TG. Post-thaw non-cultured and post-thaw cultured equine cord blood mesenchymal stromal cells equally suppress lymphocyte proliferation in vitro.. PLoS One 2014;9(12):e113615.
    doi: 10.1371/journal.pone.0113615pmc: PMC4249887pubmed: 25438145google scholar: lookup
  9. Co C, Vickaryous MK, Koch TG. Membrane culture and reduced oxygen tension enhances cartilage matrix formation from equine cord blood mesenchymal stromal cells in vitro.. Osteoarthritis Cartilage 2014 Mar;22(3):472-80.
    doi: 10.1016/j.joca.2013.12.021pubmed: 24418676google scholar: lookup
  10. Tessier L, Bienzle D, Williams LB, Koch TG. Phenotypic and immunomodulatory properties of equine cord blood-derived mesenchymal stromal cells.. PLoS One 2015;10(4):e0122954.
    doi: 10.1371/journal.pone.0122954pmc: PMC4406608pubmed: 25902064google scholar: lookup
  11. Becerra P, Valdés Vázquez MA, Dudhia J, Fiske-Jackson AR, Neves F, Hartman NG, Smith RK. Distribution of injected technetium(99m)-labeled mesenchymal stem cells in horses with naturally occurring tendinopathy.. J Orthop Res 2013 Jul;31(7):1096-102.
    doi: 10.1002/jor.22338pubmed: 23508674google scholar: lookup
  12. Broeckx S, Borena BM, Zimmerman M, Mariën T, Seys B, Suls M, Duchateau L, Spaas JH. Intravenous application of allogenic peripheral blood-derived mesenchymal stem cells: a safety assessment in 291 equine recipients.. Curr Stem Cell Res Ther 2014;9(6):452-7.
    doi: 10.2174/1574888X09666140220003847pubmed: 24548143google scholar: lookup
  13. Carrade DD, Lame MW, Kent MS, Clark KC, Walker NJ, Borjesson DL. Comparative Analysis of the Immunomodulatory Properties of Equine Adult-Derived Mesenchymal Stem Cells().. Cell Med 2012;4(1):1-11.
    doi: 10.3727/215517912X647217pmc: PMC3495591pubmed: 23152950google scholar: lookup
  14. Pigott JH, Ishihara A, Wellman ML, Russell DS, Bertone AL. Inflammatory effects of autologous, genetically modified autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses.. Vet Comp Orthop Traumatol 2013;26(6):453-60.
    doi: 10.3415/VCOT-13-01-0008pubmed: 24080668google scholar: lookup
  15. Ferris DJ, Frisbie DD, Kisiday JD, McIlwraith CW, Hague BA, Major MD, Schneider RK, Zubrod CJ, Kawcak CE, Goodrich LR. Clinical outcome after intra-articular administration of bone marrow derived mesenchymal stem cells in 33 horses with stifle injury.. Vet Surg 2014 Mar;43(3):255-65.
    doi: 10.1111/j.1532-950X.2014.12100.xpubmed: 24433318google scholar: lookup
  16. Williams LB, Koenig JB, Black B, Gibson TW, Sharif S, Koch TG. Equine allogeneic umbilical cord blood derived mesenchymal stromal cells reduce synovial fluid nucleated cell count and induce mild self-limiting inflammation when evaluated in an lipopolysaccharide induced synovitis model.. Equine Vet J 2016 Sep;48(5):619-25.
    doi: 10.1111/evj.12477pubmed: 26114736google scholar: lookup
  17. Carrade DD, Affolter VK, Outerbridge CA, Watson JL, Galuppo LD, Buerchler S, Kumar V, Walker NJ, Borjesson DL. Intradermal injections of equine allogeneic umbilical cord-derived mesenchymal stem cells are well tolerated and do not elicit immediate or delayed hypersensitivity reactions.. Cytotherapy 2011 Nov;13(10):1180-92.
    doi: 10.3109/14653249.2011.602338pubmed: 21899391google scholar: lookup
  18. Kang JG, Park SB, Seo MS, Kim HS, Chae JS, Kang KS. Characterization and clinical application of mesenchymal stem cells from equine umbilical cord blood.. J Vet Sci 2013;14(3):367-71.
    doi: 10.4142/jvs.2013.14.3.367pmc: PMC3788164pubmed: 23820166google scholar: lookup
  19. Caniglia CJ, Schramme MC, Smith RK. The effect of intralesional injection of bone marrow derived mesenchymal stem cells and bone marrow supernatant on collagen fibril size in a surgical model of equine superficial digital flexor tendonitis.. Equine Vet J 2012 Sep;44(5):587-93.
    doi: 10.1111/j.2042-3306.2011.00514.xpubmed: 22150794google scholar: lookup
  20. Godwin EE, Young NJ, Dudhia J, Beamish IC, Smith RK. Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon.. Equine Vet J 2012 Jan;44(1):25-32.
    doi: 10.1111/j.2042-3306.2011.00363.xpubmed: 21615465google scholar: lookup
  21. Nixon AJ, Dahlgren LA, Haupt JL, Yeager AE, Ward DL. Effect of adipose-derived nucleated cell fractions on tendon repair in horses with collagenase-induced tendinitis.. Am J Vet Res 2008 Jul;69(7):928-37.
    doi: 10.2460/ajvr.69.7.928pubmed: 18593247google scholar: lookup
  22. Pigott JH, Ishihara A, Wellman ML, Russell DS, Bertone AL. Investigation of the immune response to autologous, allogeneic, and xenogeneic mesenchymal stem cells after intra-articular injection in horses.. Vet Immunol Immunopathol 2013 Nov 15;156(1-2):99-106.
    doi: 10.1016/j.vetimm.2013.09.003pubmed: 24094688google scholar: lookup
  23. Nikolaev NI, Liu Y, Hussein H, Williams DJ. The sensitivity of human mesenchymal stem cells to vibration and cold storage conditions representative of cold transportation.. J R Soc Interface 2012 Oct 7;9(75):2503-15.
    doi: 10.1098/rsif.2012.0271pmc: PMC3427524pubmed: 22628214google scholar: lookup
  24. Garvican ER, Cree S, Bull L, Smith RK, Dudhia J. Viability of equine mesenchymal stem cells during transport and implantation.. Stem Cell Res Ther 2014 Aug 8;5(4):94.
    doi: 10.1186/scrt483pmc: PMC4247703pubmed: 25107289google scholar: lookup
  25. Baust JM, Van Buskirk R, Baust JG. Modulation of the cryopreservation cap: elevated survival with reduced dimethyl sulfoxide concentration.. Cryobiology 2002 Oct;45(2):97-108.
    doi: 10.1016/S0011-2240(02)00100-1pubmed: 12482375google scholar: lookup
  26. Bessems M, Doorschodt BM, van Vliet AK, van Gulik TM. Preservation of rat livers by cold storage: a comparison between the University of Wisconsin solution and Hypothermosol.. Ann Transplant 2004;9(2):35-7.
    pubmed: 15478915
  27. Cook JR, Eichelberger H, Robert S, Rauch J, Baust JG, Taylor MJ, Buskirk RG. Cold-Storage of Synthetic Human Epidermis in HypoThermosol.. Tissue Eng 1995 Winter;1(4):361-77.
    doi: 10.1089/ten.1995.1.361pubmed: 19877900google scholar: lookup
  28. Dahdah NS, Taylor MJ, Russo P, Wagerle LC. Effects of hypothermosol, an experimental acellular solution for tissue preservation and cardiopulmonary bypass, on isolated newborn lamb coronary vessels subjected to ultra profound hypothermia and anoxia.. Cryobiology 1999 Aug;39(1):58-68.
    doi: 10.1006/cryo.1999.2185pubmed: 10458901google scholar: lookup
  29. Ginis I, Grinblat B, Shirvan MH. Evaluation of bone marrow-derived mesenchymal stem cells after cryopreservation and hypothermic storage in clinically safe medium.. Tissue Eng Part C Methods 2012 Jun;18(6):453-63.
    doi: 10.1089/ten.TEC.2011.0395pubmed: 22196031google scholar: lookup
  30. Mathew AJ, Baust JM, Van Buskirk RG, Baust JG. Cell preservation in reparative and regenerative medicine: evolution of individualized solution composition.. Tissue Eng 2004 Nov-Dec;10(11-12):1662-71.
    doi: 10.1089/ten.2004.10.1662pubmed: 15684675google scholar: lookup
  31. Sosef MN, Baust JM, Sugimachi K, Fowler A, Tompkins RG, Toner M. Cryopreservation of isolated primary rat hepatocytes: enhanced survival and long-term hepatospecific function.. Ann Surg 2005 Jan;241(1):125-33.
    doi: 10.1097/01.sla.0000149303.48692.0fpmc: PMC1356855pubmed: 15622000google scholar: lookup
  32. Bismarck D, Schütze N, Moore P, Büttner M, Alber G, Buttlar Hv. Canine CD4+CD8+ double positive T cells in peripheral blood have features of activated T cells.. Vet Immunol Immunopathol 2012 Oct 15;149(3-4):157-66.
    doi: 10.1016/j.vetimm.2012.06.014pubmed: 22789871google scholar: lookup
  33. Blue ML, Daley JF, Levine H, Schlossman SF. Coexpression of T4 and T8 on peripheral blood T cells demonstrated by two-color fluorescence flow cytometry.. J Immunol 1985 Apr;134(4):2281-6.
    pubmed: 2982943
  34. Luhtala M, Lassila O, Toivanen P, Vainio O. A novel peripheral CD4+ CD8+ T cell population: inheritance of CD8alpha expression on CD4+ T cells.. Eur J Immunol 1997 Jan;27(1):189-93.
    doi: 10.1002/eji.1830270128pubmed: 9022017google scholar: lookup
  35. Pescovitz MD, Sakopoulos AG, Gaddy JA, Husmann RJ, Zuckermann FA. Porcine peripheral blood CD4+/CD8+ dual expressing T-cells.. Vet Immunol Immunopathol 1994 Oct;43(1-3):53-62.
    doi: 10.1016/0165-2427(94)90120-1pubmed: 7856064google scholar: lookup
  36. Pescovitz MD, Hsu SM, Katz SI, Lunney JK, Shimada S, Sachs DH. Characterization of a porcine CD1-specific mAb that distinguishes CD4/CD8 double-positive thymic from peripheral T lymphocytes.. Tissue Antigens 1990 Apr;35(4):151-6.
    doi: 10.1111/j.1399-0039.1990.tb01772.xpubmed: 1695393google scholar: lookup
  37. Ranera B, Antczak D, Miller D, Doroshenkova T, Ryan A, McIlwraith CW, Barry F. Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes.. Equine Vet J 2016 Mar;48(2):253-60.
    doi: 10.1111/evj.12414pubmed: 25582202google scholar: lookup
  38. Zuckermann FA. Extrathymic CD4/CD8 double positive T cells.. Vet Immunol Immunopathol 1999 Dec 15;72(1-2):55-66.
    doi: 10.1016/S0165-2427(99)00118-Xpubmed: 10614493google scholar: lookup
  39. Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far?. Immunol Cell Biol 2013 Jan;91(1):40-51.
    doi: 10.1038/icb.2012.67pubmed: 23207278google scholar: lookup
  40. Wilmink JM, Veenman JN, van den Boom R, Rutten VP, Niewold TA, Broekhuisen-Davies JM, Lees R, Armstrong S, van Weeren PR, Barneveld A. Differences in polymorphonucleocyte function and local inflammatory response between horses and ponies.. Equine Vet J 2003 Sep;35(6):561-9.
    doi: 10.2746/042516403775467234pubmed: 14515955google scholar: lookup
  41. Wilmink JM, van Weeren PR, Stolk PW, Van Mil FN, Barneveld A. Differences in second-intention wound healing between horses and ponies: histological aspects.. Equine Vet J 1999 Jan;31(1):61-7.
    doi: 10.1111/j.2042-3306.1999.tb03792.xpubmed: 9952331google scholar: lookup
  42. Taylor MJ, Bailes JE, Elrifai AM, Shih TS, Teeple E, Leavitt ML, Baust JC, Maroon JC. Asanguineous whole body perfusion with a new intracellular acellular solution and ultraprofound hypothermia provides cellular protection during 3.5 hours of cardiac arrest in a canine model.. ASAIO J 1994 Jul-Sep;40(3):M351-8.
    doi: 10.1097/00002480-199407000-00022pubmed: 8555538google scholar: lookup
  43. Taylor MJ, Bailes JE, Elrifai AM, Shih SR, Teeple E, Leavitt ML, Baust JG, Maroon JC. A new solution for life without blood. Asanguineous low-flow perfusion of a whole-body perfusate during 3 hours of cardiac arrest and profound hypothermia.. Circulation 1995 Jan 15;91(2):431-44.
    doi: 10.1161/01.CIR.91.2.431pubmed: 7805248google scholar: lookup

Citations

This article has been cited 10 times.
  1. Ho YK, Loke KM, Woo JY, Lee YL, Too HP. Cryopreservation does not change the performance and characteristics of allogenic mesenchymal stem cells highly over-expressing a cytoplasmic therapeutic transgene for cancer treatment.. Stem Cell Res Ther 2022 Nov 14;13(1):519.
    doi: 10.1186/s13287-022-03198-zpubmed: 36376945google scholar: lookup
  2. Taylor SD, Serpa PBS, Santos AP, Hart KA, Vaughn SA, Moore GE, Mukhopadhyay A, Page AE. Effects of intravenous administration of peripheral blood-derived mesenchymal stromal cells after infusion of lipopolysaccharide in horses.. J Vet Intern Med 2022 Jul;36(4):1491-1501.
    doi: 10.1111/jvim.16447pubmed: 35698909google scholar: lookup
  3. Mund SJK, MacPhee DJ, Campbell J, Honaramooz A, Wobeser B, Barber SM. Macroscopic, Histologic, and Immunomodulatory Response of Limb Wounds Following Intravenous Allogeneic Cord Blood-Derived Multipotent Mesenchymal Stromal Cell Therapy in Horses.. Cells 2021 Nov 1;10(11).
    doi: 10.3390/cells10112972pubmed: 34831196google scholar: lookup
  4. Lee OJ, Koch TG. Steps Toward Standardized In Vitro Assessment of Immunomodulatory Equine Mesenchymal Stromal Cells Before Clinical Application.. Stem Cells Dev 2022 Jan;31(1-2):18-25.
    doi: 10.1089/scd.2021.0189pubmed: 34779250google scholar: lookup
  5. Mund SJK, Kawamura E, Awang-Junaidi AH, Campbell J, Wobeser B, MacPhee DJ, Honaramooz A, Barber S. Homing and Engraftment of Intravenously Administered Equine Cord Blood-Derived Multipotent Mesenchymal Stromal Cells to Surgically Created Cutaneous Wound in Horses: A Pilot Project.. Cells 2020 May 8;9(5).
    doi: 10.3390/cells9051162pubmed: 32397125google scholar: lookup
  6. MacDonald ES, Barrett JG. The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses.. Front Vet Sci 2019;6:507.
    doi: 10.3389/fvets.2019.00507pubmed: 32039250google scholar: lookup
  7. Petrenko Y, Chudickova M, Vackova I, Groh T, Kosnarova E, Cejkova J, Turnovcova K, Petrenko A, Sykova E, Kubinova S. Clinically Relevant Solution for the Hypothermic Storage and Transportation of Human Multipotent Mesenchymal Stromal Cells.. Stem Cells Int 2019;2019:5909524.
    doi: 10.1155/2019/5909524pubmed: 30805009google scholar: lookup
  8. Kim G, Park YS, Lee Y, Jin YM, Choi DH, Ryu KH, Park YJ, Park KD, Jo I. Tonsil-derived mesenchymal stem cell-embedded in situ crosslinkable gelatin hydrogel therapy recovers postmenopausal osteoporosis through bone regeneration.. PLoS One 2018;13(7):e0200111.
    doi: 10.1371/journal.pone.0200111pubmed: 29975738google scholar: lookup
  9. Gurruchaga H, Saenz Del Burgo L, Garate A, Delgado D, Sanchez P, Orive G, Ciriza J, Sanchez M, Pedraz JL. Cryopreservation of Human Mesenchymal Stem Cells in an Allogeneic Bioscaffold based on Platelet Rich Plasma and Synovial Fluid.. Sci Rep 2017 Nov 16;7(1):15733.
    doi: 10.1038/s41598-017-16134-6pubmed: 29146943google scholar: lookup
  10. Textor JA, Clark KC, Walker NJ, Aristizobal FA, Kol A, LeJeune SS, Bledsoe A, Davidyan A, Gray SN, Bohannon-Worsley LK, Woolard KD, Borjesson DL. Allogeneic Stem Cells Alter Gene Expression and Improve Healing of Distal Limb Wounds in Horses.. Stem Cells Transl Med 2018 Jan;7(1):98-108.
    doi: 10.1002/sctm.17-0071pubmed: 29063737google scholar: lookup
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.